长期恩替卡韦治疗后换用丙酚替诺福韦的序贯治疗结局
多中心回顾性研究纳入425例经恩替卡韦治疗至少12个月的慢性乙型肝炎患者,换用丙酚替诺福韦后随访至96周。完全病毒抑制率从换药时91.90%升至48周95.57%和96周97.21%,平均HBV DNA下降,但丙氨酸氨基转移酶和慢性肾病分期无显著变化。
要点
- 恩替卡韦经治患者换用丙酚替诺福韦后完全病毒抑制率从91.9%升至96周97.2%
- 换药后平均HBV DNA显著下降,但ALT和CKD分期无显著变化
- 基线eGFR、年龄及CKD分期2和3-5与随访eGFR较低相关
核心结论
- 平均恩替卡韦治疗6年后换用丙酚替诺福韦,完全病毒抑制率从换药时91.9%增至96周97.2%。
研究设计与样本
- 多中心回顾性研究,纳入15个中心(美国、韩国、日本、台湾)经恩替卡韦治疗至少12个月后换用丙酚替诺福韦的慢性乙型肝炎患者425例。
主要发现
- 完全病毒抑制率从换药时91.90%升至48周95.57%(P=0.03)和96周97.21%(P=0.02)。
- 换药后96周内平均HBV DNA下降(P<0.001),但丙氨酸氨基转移酶和CKD分期无显著变化。
- 换药至96周随访,CKD分期1期患者11%(26/235)迁移至2期,2期患者8%(12/151)迁移至3-5期;2期18%(27/151)迁移至1期,3-5期19%(7/37)迁移至2期。
- 多变量分析调整年龄、性别、高血压、糖尿病和肝硬化后,基线eGFR、年龄(P<0.001)及CKD分期2和3-5(对比1期)(均P<0.001)与随访eGFR较低相关。
临床怎么用
- 长期恩替卡韦治疗的慢性乙型肝炎患者可考虑换用丙酚替诺福韦以进一步提高完全病毒抑制率。
- 换药后需关注肾功能变化,尤其基线eGFR较低、高龄或CKD分期2及以上患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch. METHODS: ETV-treated (≥12 months) chronic hepatitis B patients switched to TAF in routine practice at 15 centers (United States, Korea, Japan, and Taiwan) were included. Primary outcome was complete viral suppression (CVS) rate (HBV DNA <20 IU/mL). RESULTS: We analyzed 425 eligible patients (mean age 60.7 ± 13.2 years, 60% men, 90.8% Asian, 20.7% with diabetes, 27% with hypertension, 14.8% with cirrhosis, 8.3% with hepatocellular carcinoma, and mean ETV duration before switch 6.16 ± 3.17 years). The mean baseline estimated glomerular filtration rate (eGFR) was 89 ± 19 (chronic kidney disease [CKD] stages: 55.6% stage 1, 35.7% stage 2, and 8.8% stages 3-5). CVS rate increased from 91.90% at switch (from 90.46% 24 weeks before switch) to 95.57% and 97.21% at 48 and 96 weeks after (P = 0.03 and 0.02, respectively). Over the 96 weeks after switch, mean HBV DNA (P < 0.001) but not alanine aminotransferase or CKD stage decreased. Between switch and 96-week follow-up, 11% (26/235) of CKD stage 1 patients migrated to stage 2 and 8% (12/151) of stage 2 patients to stages 3-5, whereas 18% (27/151) from stage 2 to 1, and 19% (7/37) from stages 3-5 to 2. On multivariable generalized estimated equation analysis adjusted for age, sex, hypertension, diabetes, and cirrhosis, baseline eGFR, age (P < 0.001), and CKD stages 2 and 3-5 (vs 1) (both P < 0.001) were associated with lower follow-up eGFR. DISCUSSION: After an average of 6 years on ETV, CVS increased from 91.9% at TAF switch to 97.2% at 96 weeks later.
引用
- Nguyen MH, Atsukawa M, Ishikawa T, et al. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. Am J Gastroenterol. 2021. PMID: 34074829. doi:10.14309/ajg.0000000000001157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。